Posts classified under: GBM AGILE

News + Announcements

Global Coalition for Adaptive Research in Collaboration with Cure Brain Cancer Foundation Announce the Opening of Glioblastoma Clinical Trial in Australia

November 14, 2023 | BUSINESSWIRE

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

October 31, 2023 | PRNewswire

Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial

August 15, 2023 | BUSINESSWIRE

Global Coalition for Adaptive Research and GBM AGILE Partners to Ring The Nasdaq Stock Market Closing Bell in Honor of National Brain Tumor Awareness Month

May 19, 2023 | BUSINESSWIRE

Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma

September 21, 2022 | BUSINESSWIRE

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM AGILE Trial

July 6, 2022 | BUSINESSWIRE

GBM AGILE Opens to Paxalisib in Europe

May 31, 2022 | KAZIA THERAPEUTICS

Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma

May 27, 2022 | PRNEWSWIRE

Cure Brain Cancer Foundation invests in GBM AGILE, connecting Australians to an innovative clinical trial program to treat glioblastoma

February 22, 2022 | CURE BRAIN CANCER FOUNDATION

Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma

January 18, 2022 | BUSINESSWIRE

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

November 30, 2021 | PRNEWSWIRE

GBM AGILE Opens to Paxalisib in Canada

November 29, 2021 | KAZIA THERAPEUTICS

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma

February 3, 2021 | NEWSWISE

Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial

January 6, 2021 | BUSINESSWIRE

Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study

October 21, 2020 | PRNEWSWIRE

Kazia Executes Agreement to Commence GBM AGILE Pivotal Study

October 16, 2020 | KAZIA THERAPEUTICS

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

June 24, 2020 | PRNEWSWIRE

Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals’ VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme

June 4, 2020 | PRNEWSWIRE

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14, 2020 | ONCLIVE

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

December 11, 2019 | PRNEWSWIRE

Bayer’s Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer

June 19, 2019 | PRNEWSWIRE

Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer

June 19, 2019 | BUSINESSWIRE

New Funding & Partnership Bolsters Support for First Global Adaptive Clinical Trial Platform for Brain Cancer Patients

May 1, 2019 | NATIONAL BRAIN TUMOR SOCIETY

National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma

January 16, 2019 | NATIONAL BRAIN TUMOR SOCIETY

Bayer’s Regorafenib is the First Drug to Enter GBM AGILE

November 14, 2018 | BUSINESSWIRE